Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0BRYOM
ADC Name
WO2017214024A1 ADC-103
Synonyms
WO2017214024A1 ADC-103
   Click to Show/Hide
Organization
Genentech, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Investigative
Drug-to-Antibody Ratio
2
Antibody Name
Thio hu Anti-HER2 7C2 LC K149C
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
WO2017214024A1_ADC-103 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 26.29
%
BJAB cells
Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
≈ 36.16
%
BJAB cells
Burkitt lymphoma
Tumor Growth Inhibition value (TGI) 
≈ 47.36
%
KPL-4 cells
Breast inflammatory carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 76.36
%
KPL-4 cells
Breast inflammatory carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 98.03
%
KPL-4 cells
Breast inflammatory carcinoma
Tumor Growth Inhibition value (TGI) 
≈ 99.38
%
KPL-4 cells
Breast inflammatory carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 26.29% (Day 17) Moderate CD22 expression (CD22++)
Method Description
Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (10 mg/kg) via the tail vein on Day 0.

   Click to Show/Hide
In Vivo Model BJAB CDX model
In Vitro Model Burkitt lymphoma BJAB cells CVCL_5711
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 36.16% (Day 14) Moderate CD22 expression (CD22++)
Method Description
Inoculate 150 mice with BJAB cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously (3 mg/kg) via the tail vein on Day 0.

   Click to Show/Hide
In Vivo Model BJAB CDX model
In Vitro Model Burkitt lymphoma BJAB cells CVCL_5711
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 47.36% (Day 26) Positive HER2 expression (HER2+++/++)
Method Description
Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (1 mg/kg) via the tail vein on Day 0.

   Click to Show/Hide
In Vivo Model KPL-4 CDX model
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 76.36% (Day 26) Positive HER2 expression (HER2+++/++)
Method Description
Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (3 mg/kg) via the tail vein on Day 0.

   Click to Show/Hide
In Vivo Model KPL-4 CDX model
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 98.03% (Day 26) Positive HER2 expression (HER2+++/++)
Method Description
Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (6 mg/kg) via the tail vein on Day 0.

   Click to Show/Hide
In Vivo Model KPL-4 CDX model
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 99.38% (Day 26) Positive HER2 expression (HER2+++/++)
Method Description
Inoculate 150 mice with KPL-4 cells at 3 million cells/mouse suspended in HBSS/matrigel, in the thoracic mammary fat pad at a volume of 0.2 ml. When tumors have reached a mean tumor volume of 100-250 mm3, they will be grouped out into 10 groups of 8-10 mice each. A single treatment will be administered intravenously ADC (10 mg/kg) via the tail vein on Day 0.

   Click to Show/Hide
In Vivo Model KPL-4 CDX model
In Vitro Model Breast inflammatory carcinoma KPL-4 cells CVCL_5310
References
Ref 1 Silvestrol antibody-drug conjugates and methods of use; 2017-12-14.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.